

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和 鉑 醫 藥 控 股 有 限 公 司**  
**HBM Holdings Limited**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02142)**

**VOLUNTARY ANNOUNCEMENT**  
**DOSING OF FIRST PATIENT IN**  
**TANFANERCEPT (HBM9036) PHASE III CLINICAL TRIAL**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors (the “**Board**”) of the Company today announced the dosing of the first patient in the phase III clinical trial of tanfanercept (HBM9036), a new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug for adult patients with moderate-to-severe dry eye disease (DED) in China. The purpose of this phase III clinical trial is to evaluate the effectiveness and safety of tanfanercept (HBM9036) eye drops (0.25%) compared with placebo in the treatment of moderate-to-severe DED patients in China.

**About Tanfanercept (HBM9036)**

Tanfanercept (HBM9036) is a modified 19 kDa TNF receptor 1 fragment. It is molecularly engineered as a therapy for relief of the signs and symptoms of DED and was specifically developed for ophthalmic topical use with good eye permeability, strong TNF- $\alpha$  neutralizing activity, high stability, and minor side effects. It is originally developed by HanAll Biopharma and, based on a licensing agreement, the Group owns the exclusive rights for development and commercialization of tanfanercept (HBM9036) in mainland China, Taiwan, Hong Kong, and Macao.

**About Dry Eye Disease (DED)**

DED is a chronic, multifactorial ocular disease that can cause visual disturbance and long-term damage of the ocular surface, with a significant impact on quality of life. The prevalence of this ocular disease is expected to grow significantly fueled by a growing aging population worldwide, excessive use of smartphones, and environmental changes. Artificial tears, which only provide temporary symptomatic relief, are still the most used treatment for DED in China, representing a large unmet need in the Chinese market.

**Cautionary Statement:** we cannot guarantee that we will be able to develop, or ultimately market, tanfanercept (HBM9036) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

**Company website:** [www.harbourbiomed.com](http://www.harbourbiomed.com)

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 11 March 2021

*As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang, Dr. Mai-Jing Liao, and Dr. Atul Mukund Deshpande as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.*